CENTOGENE nominates Dr. Jonathan Sheldon for election to its Supervisory Board

– GERMANY, Rostock –  CENTOGENE (Nasdaq: CNTG), a commercial-stage company focused on rare diseases that transforms real-world clinical and genetic data into actionable information for patients, physicians, and pharmaceutical companies, today announced the nomination of Dr. Jonathan Sheldon for the upcoming election to its Supervisory Board.

“We are excited to welcome Dr. Jonathan Sheldon as a new member of the Supervisory Board. Jonathan has been instrumental in building QIAGEN’s leading data interpretation offerings for scientific and clinical decision support. We look forward to benefiting from his contributions as we advance the use of CENTOGENE’s data repositories, which we believe to be by far the most comprehensive collection of such data in rare diseases,” stated Dr. Flemming Ornskov, Chairman of the Supervisory Board.

About Dr. Jonathan Sheldon

Dr. Sheldon serves as SVP of the Digital Insights Business Area at QIAGEN N.V. (Nasdaq: QGEN | FRA: QIA), a leading provider of molecular sample and assay technologies. Since 2018, he has led QIAGEN’s Digital Insights global business. Before this, Jonathan served as Global VP at Oracle Health Sciences from 2010-2017.

About CENTOGENE

CENTOGENE engages in diagnosis and research around rare diseases transforming real-world clinical and genetic data into actionable information for patients, physicians, and pharmaceutical companies. Our goal is to bring rationality to treatment decisions and to accelerate the development of new orphan drugs by using our extensive rare disease knowledge, including epidemiological and clinical data, as well as innovative biomarkers. CENTOGENE has developed a global proprietary rare disease platform based on our real-world data repository with over 3.6 billion weighted data points from approximately 570,000 patients representing over 120 different countries as of August 31, 2020.

The Company’s platform includes epidemiologic, phenotypic, and genetic data that reflects a global population, and also a biobank of these patients’ blood samples. CENTOGENE believes this represents the only platform that comprehensively analyzes multi-level data to improve the understanding of rare hereditary diseases, which can aid in the identification of patients and improve our pharmaceutical partners’ ability to bring orphan drugs to the market. As of August 31, 2020, the Company collaborated with over 40 pharmaceutical partners covering over 45 different rare diseases.

For more information: https://www.centogene.com/

- DisclaimerNews, data, and statements included in this release are intended exclusively for general information purposes. Talent4Boards does not guarantee that news is accurate or about the correct person and accepts neither liability for the consequences of the reader’s reliance, nor responsibility for the accuracy of the information. Nothing in this release should be considered for decisions about referred securities. Products and brand names may be trademarks or registered trademarks of their respective owners.

Talent4Boards Team